TWI923583B - 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物 - Google Patents

包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物

Info

Publication number
TWI923583B
TWI923583B TW110113031A TW110113031A TWI923583B TW I923583 B TWI923583 B TW I923583B TW 110113031 A TW110113031 A TW 110113031A TW 110113031 A TW110113031 A TW 110113031A TW I923583 B TWI923583 B TW I923583B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
tablet
microcrystalline cellulose
mesylate
mannitol
Prior art date
Application number
TW110113031A
Other languages
English (en)
Chinese (zh)
Other versions
TW202207940A (zh
Inventor
杰奎琳 瑪克西米利安
高普 拉君
Original Assignee
美商健生生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健生生物科技公司 filed Critical 美商健生生物科技公司
Publication of TW202207940A publication Critical patent/TW202207940A/zh
Application granted granted Critical
Publication of TWI923583B publication Critical patent/TWI923583B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW110113031A 2020-04-14 2021-04-12 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物 TWI923583B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063009623P 2020-04-14 2020-04-14
US63/009,623 2020-04-14
US202063014277P 2020-04-23 2020-04-23
US63/014,277 2020-04-23

Publications (2)

Publication Number Publication Date
TW202207940A TW202207940A (zh) 2022-03-01
TWI923583B true TWI923583B (zh) 2026-05-01

Family

ID=75562794

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110113031A TWI923583B (zh) 2020-04-14 2021-04-12 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物

Country Status (13)

Country Link
US (2) US12138351B2 (cg-RX-API-DMAC10.html)
EP (1) EP4135669A1 (cg-RX-API-DMAC10.html)
JP (2) JP7787824B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230002656A (cg-RX-API-DMAC10.html)
CN (1) CN115484937A (cg-RX-API-DMAC10.html)
AU (2) AU2021257662B2 (cg-RX-API-DMAC10.html)
CA (1) CA3180184A1 (cg-RX-API-DMAC10.html)
IL (1) IL297240A (cg-RX-API-DMAC10.html)
MX (1) MX2022012898A (cg-RX-API-DMAC10.html)
PH (1) PH12022552454A1 (cg-RX-API-DMAC10.html)
TW (1) TWI923583B (cg-RX-API-DMAC10.html)
UY (1) UY39171A (cg-RX-API-DMAC10.html)
WO (1) WO2021209893A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
EP4349835A4 (en) * 2021-06-01 2025-06-25 Hangzhou Solipharma Co., Ltd. Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof
WO2023138492A1 (zh) * 2022-01-19 2023-07-27 南京明德新药研发有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131505A1 (en) * 2006-10-27 2008-06-05 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
WO2017176965A1 (en) * 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
WO2018194356A1 (en) * 2017-04-21 2018-10-25 Yuhan Corporation Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437006B1 (en) * 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
US6399591B1 (en) 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
ES2713330T3 (es) 2009-12-11 2019-05-21 Sumitomo Dainippon Pharma Co Ltd Comprimido recubierto en seco que se desintegra oralmente
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US20160151380A1 (en) * 2013-07-12 2016-06-02 The Regents Of The University Of California Therapies for diseases caused by arthropod-borne parasites
MY179355A (en) 2013-12-12 2020-11-05 Almirall Sa Pharmaceutical compositions comprising dimethyl fumarate
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
UA126970C2 (uk) * 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку
JP2020510027A (ja) * 2017-03-08 2020-04-02 アリアド ファーマシューティカルズ，インコーポレーテッド ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤
DK3658547T3 (da) 2017-07-28 2023-10-16 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
RS63497B1 (sr) 2017-07-28 2022-09-30 Yuhan Corp Intermedijeri korisni za sintezu derivata aminopirimidina, proces za pripremu istih i proces za pripremu derivata aminopirimidina korišćenjem istih
ES2962961T3 (es) 2017-07-28 2024-03-22 Yuhan Corp Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
CN110580014B (zh) * 2018-06-11 2021-03-30 北京京东尚科信息技术有限公司 用于控制自动导引运输车的方法、装置和系统
US12350734B2 (en) 2018-07-20 2025-07-08 Imerys Usa, Inc. Recovering sand, bentonite and organics from foundry sand waste
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
CN113784704A (zh) 2019-04-17 2021-12-10 诺狄更斯公司 快速崩解大麻素片剂
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MX2022001159A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Nueva formulacion farmaceutica.
TW202228689A (zh) * 2020-10-09 2022-08-01 美商賽若凡斯生物製藥研發智財有限責任公司 泛ｊａｋ抑制劑的調配物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131505A1 (en) * 2006-10-27 2008-06-05 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
WO2017176965A1 (en) * 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
WO2018194356A1 (en) * 2017-04-21 2018-10-25 Yuhan Corporation Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Also Published As

Publication number Publication date
TW202207940A (zh) 2022-03-01
JP2025179094A (ja) 2025-12-09
JP2023522634A (ja) 2023-05-31
UY39171A (es) 2021-10-29
BR112022020609A2 (pt) 2022-11-29
WO2021209893A1 (en) 2021-10-21
AU2021257662B2 (en) 2025-06-12
IL297240A (en) 2022-12-01
EP4135669A1 (en) 2023-02-22
CN115484937A (zh) 2022-12-16
US20250177311A1 (en) 2025-06-05
CA3180184A1 (en) 2021-10-21
MX2022012898A (es) 2023-01-24
US12138351B2 (en) 2024-11-12
KR20230002656A (ko) 2023-01-05
PH12022552454A1 (en) 2024-02-05
AU2025203347A1 (en) 2025-05-29
US20210322323A1 (en) 2021-10-21
WO2021209893A8 (en) 2022-10-13
AU2021257662A1 (en) 2022-12-15
JP7787824B2 (ja) 2025-12-17

Similar Documents

Publication Publication Date Title
JP7787824B2 (ja) アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物
EP2623100B1 (en) Preparation for improving solubility of poorly soluble drug
TWI831848B (zh) 用於口服投予之包含胺基嘧啶衍生物或其鹽的醫藥組成物
JP6124799B2 (ja) 低溶解性医薬活性成分を含む医薬組成物の調製方法
HK1243947A1 (en) Apixaban formulations
HK1243945A1 (en) Apixaban formulations
EP2964200B1 (en) Formulations of organic compounds
JPWO2002024166A1 (ja) 崩壊性が良好な経口製剤
JP2023027312A (ja) ５－クロロ－ｎ４－［２－（ジメチルホスホリル）フェニル］－ｎ２－｛２－メトキシ－４－［４－（４－メチルピペラジン－１－イル）ピペリジン－１－イル］フェニル｝ピリミジン－２，４－ジアミンを含む医薬製剤
JP7809780B2 (ja) 粒状組成物、粒状組成物の製造方法、および粒状組成物の溶出性改善方法
EP4262760B1 (en) Edoxaban formulation containing no sugar alcohols
EP2620140A1 (en) Crizotinib containing compositions
WO2012172461A1 (en) Pharmaceutical compositions of febuxostat
US20140093563A1 (en) Febuxostat compositions
EP3601277B1 (en) Pharmaceutical formulation
KR20250022143A (ko) 피미테스핍을 함유하는 의약 조성물
BR112022020609B1 (pt) Composição e formulação farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo e seus usos
HK40085907A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
EA048109B1 (ru) Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его фармацевтически приемлемую соль, гидрат или сольват
EP3466413A1 (en) Pharmaceutical composition containing agomelatine and process for the preparation thereof
EP4410278A1 (en) Pharmaceutical composition comprising enavogliflozin
EP3072529A1 (en) Composition comprising vemurafenib and hpmc-as
EP2881116A1 (en) Febuxostat composition
HK40105586A (en) Pharmaceutical composition comprising enavogliflozin
HK40029900A (en) Apixaban formulations